<DOC>
	<DOCNO>NCT00187707</DOCNO>
	<brief_summary>The current study part large multi-investigator grant look pharmacogenetics number membrane transporter . Previously , recruit cohort healthy volunteer ( Studies Pharmacogenetics Ethnically-diverse Populations , SOPHIE ) resequenced cod region number membrane transporter gene identify genetic polymorphism gene . We plan take genotype-to-phenotype approach study influence specific polymorphisms intestinal transporter , novel organic cation transporter 1 2 ( OCTN1 OCTN2 ) gene bioavailability gabapentin healthy subject . Eligible subject single inpatient study visit , take single dose gabapentin , provide blood urine sample course 36 hour ( 5 terminal elimination gabapentin half-lives ) pharmacokinetic analysis .</brief_summary>
	<brief_title>Influence Intestinal Transporter Genetic Variants Bioavailability Gabapentin</brief_title>
	<detailed_description>Detailed description pending</detailed_description>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Subjects must previously participate `` SOPHIE '' study . Subjects age 18 40 year old Subjects select healthy medical history questionnaire screen blood work ( CBC , Comprehensive Metabolic panel ) . Subjects take regular medication normal renal function . Pregnant Have new history indicating longer healthy ; Individuals anemia ( hemoglobin &lt; 12 g/dL ) , elevation liver enzymes higher double respective normal value , elevate creatinine concentration ( male ≥ 1.5 mg/dL , females ≥ 1.4 mg/dL ) , exclude . Taking medication could confound study result Do consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>